Predictors of treatment with osteoporosis medications after recent fragility fractures in a multinational cohort of postmenopausal women

Journal of the American Geriatrics Society

Volumn 60, Issue 3, 2012, Pages 455-461

  Greenspan, Susan L ^a   Wyman, Allison ^b   Hooven, Frederick H ^b   Adami, Silvano ^c   Gehlbach, Stephen ^b   Anderson Jr , Frederick A ^b   Boone, Steven ^d   Lacroix, Andrea Z ^e   Lindsay, Robert ^f   Coen Netelenbos, J ^g   Pfeilschifter, Johannes ^h   Silverman, Stuart ⁱ   Siris, Ethel S ^j   Watts, Nelson B ^k  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c UNIVERSITY OF VERONA   (Italy)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e Fred Hutchinson Cancer Research Center   (United States)

^f HELEN HAYES HOSPITAL   (United States)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h ALFRIED KRUPP KRANKENHAUS   (Germany)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j NewYork Presbyterian Hospital   (United States)

^k UNIVERSITY OF CINCINNATI   (United States)

more..

Author keywords

fracture; osteoporosis; osteoporosis treatment

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTROGEN; PARATHYROID HORMONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; INCIDENTAL FINDING; MAJOR CLINICAL STUDY; OSTEOPOROSIS; POSTMENOPAUSE; RISK FACTOR; SPINE FRACTURE;

AGED; CHI-SQUARE DISTRIBUTION; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PROSPECTIVE STUDIES; QUESTIONNAIRES; REGRESSION ANALYSIS; RISK FACTORS;

EID: 84858335410     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2011.03854.x     Document Type: Article

References (27)

1. Schneider DL,. Management of osteoporosis in geriatric populations. Curr Osteoporos Rep 2008; 6: 100-107.
2. Cooper C,. The crippling consequences of fractures and their impact on quality of life. Am J Med 1997; 103: 12S-17S; discussion 17S-19S.
3. Cooper C, Atkinson EJ, Jacobsen SJ, et al. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993; 137: 1001-1005.
4. Bliuc D, Nguyen ND, Milch VE, et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009; 301: 513-521.
5. Davison KS, Kendler DL, Ammann P, et al. Assessing fracture risk and effects of osteoporosis drugs: Bone mineral density and beyond. Am J Med 2009; 122: 992-997.
6. Bilezikian JP,. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med 2009; 122: S14-21.
7. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation, 2008.
8. Greenspan SL,. Osteoporosis. In:, Andriole TE, Ed. Cecil's Essentials of Medicine, 8th Ed. Philadelphia, PA: Elsevier, 2010, Ch. 76.
9. Kamel HK, Hussain MS, Tariq S, et al. Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture. Am J Med 2000; 109: 326-328.
10. Gehlbach SH, Avrunin JS, Puleo E, et al. Fracture risk and antiresorptive medication use in older women in the USA. Osteoporos Int 2007; 18: 805-810.
11. Hooven FH, Adachi JD, Adami S, et al. The Global Longitudinal Study of Osteoporosis in Women (GLOW): Rationale and study design. Osteoporos Int 2009; 20: 1107-1116.
12. Brooks R,. EuroQol: The current state of play. Health Policy 1996; 37: 53-72.
13. Brazier JE, Walters SJ, Nicholl JP, et al. Using the SF-36 and EuroQol on an elderly population. Qual Life Res 1996; 5: 195-204.
14. Picavet HS, Hoeymans N,. Health related quality of life in multiple musculoskeletal diseases: SF-36 and EQ-5D in the DMC3 study. Ann Rheum Dis 2004; 63: 723-729.
15. Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: New outcome measure for primary care. BMJ 1992; 305: 160-164.
16. Lips P, van Schoor NM,. Quality of life in patients with osteoporosis. Osteoporos Int 2005; 16: 447-455.
17. Elliot-Gibson V, Bogoch ER, Jamal SA, et al. Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: A systematic review. Osteoporos Int 2004; 15: 767-778.
18. Ryder KM, Shorr RI, Tylavsky FA, et al. Correlates of use of antifracture therapy in older women with low bone mineral density. J Gen Intern Med 2006; 21: 636-641.
19. Bessette L, Ste-Marie LG, Jean S, et al. The care gap in diagnosis and treatment of women with a fragility fracture. Osteoporos Int 2008; 19: 79-86.
20. Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008; 19: 399-428.
21. Osteoporosis. Towards a Fracture-Free Future. Ontario: Osteoporosis Canada, 2011.
22. Andrade SE, Majumdar SR, Chan KA, et al. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med 2003; 163: 2052-2057.
23. Simonelli C, Killeen K, Mehle S, et al. Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. Mayo Clin Proc 2002; 77: 334-338.
24. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008; 19: 385-397.
25. Curtis JR, Westfall AO, Allison J, et al. Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users. Pharmacoepidemiol Drug Saf 2006; 15: 710-718.
26. Ismail AA, O'Neill TW, Cockerill W, et al. Validity of self-report of fractures: Results from a prospective study in men and women across Europe. EPOS Study Group. Osteoporos Int 2000; 11: 248-254.
27. Nevitt MC, Cummings SR, Browner WS, et al. The accuracy of self-report of fractures in elderly women: Evidence from a prospective study. Am J Epidemiol 1992; 135: 490-499.